文献速递瓣膜外科

LAAOS III亚组:心房颤动合并生物瓣或瓣环成形术后口服抗凝比较

Oral anticoagulation in patients with atrial fibrillation and heart valve prosthesis: A substudy from the Left Atrial Appendage Occlusion Study (LAAOS) III trial.
PubMed 文献 · J Thorac Cardiovasc Surg · 2025-09-08

该研究为LAAOS III试验的亚组分析,纳入2645例因心房颤动接受生物瓣植入或二尖瓣修复的患者,其中461例出院时使用直接口服抗凝药(DOAC),2184例使用维生素K拮抗剂(VKA)。主要终点为卒中或系统性血栓栓塞,次要终点为大出血。

要点

  • 生物瓣植入或二尖瓣修复后房颤患者,DOAC与VKA血栓栓塞风险无显著差异。
  • 两组大出血风险亦无显著差异,DOAC或可作为安全替代。
  • 抗凝中断或转换者结局有恶化趋势,但未达统计学显著性。

核心结论

  • 在LAAOS III试验中,二尖瓣和/或主动脉生物瓣植入或二尖瓣修复后出院的房颤患者,DOAC与VKA相比血栓栓塞和大出血风险相似,提示DOAC可能是安全替代。

研究设计与样本

  • LAAOS III试验的亚组分析,共纳入2645例患者,461例出院时使用DOAC,2184例使用VKA;排除机械瓣或孤立冠状动脉手术患者。
  • 采用Cox比例风险模型,校正时间依赖协变量及临床因素(如年龄、既往卒中、左心耳封堵)。

主要发现

  • DOAC组患者年龄更大、男性居多,风湿性心脏病比例低于VKA组。
  • 抗凝中断或转换的患者结局有恶化趋势,但未达统计学显著性。

临床怎么用

  • 对于生物瓣植入或二尖瓣修复后的房颤患者,DOAC可作为VKA的替代选择,但需个体化评估。
  • 抗凝中断或转换可能带来不良结局趋势,应尽量避免不必要的抗凝方案变更。

局限性

  • 本研究为LAAOS III试验的亚组分析,非随机对照比较,可能存在选择偏倚和混杂因素。
  • 原文未报告随访时长、具体DOAC种类及剂量等细节。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Societal guidelines recommend vitamin K antagonists (VKAs) for patients with atrial fibrillation with recent biological valve implantation, but the safety and efficacy of direct oral anticoagulants (DOACs) in this setting remain uncertain, especially in the early postoperative period. This substudy of the Left Atrial Appendage Occlusion Study (LAAOS) III trial aimed to compare thromboembolic and bleeding outcomes in patients discharged on VKAs versus DOACs after bioprosthesis implantation or mitral valve repair. METHODS: A total of 2645 patients were included, with 461 discharged on DOACs and 2184 on VKAs. Patients with mechanical valves or isolated coronary surgery were excluded. The primary end point was stroke or systemic thromboembolism. Major bleeding was a secondary end point. Cox proportional hazard models adjusted for time-dependent covariates and clinical factors (eg, age, previous stroke, left atrial appendage occlusion) were applied to assess outcomes. RESULTS: Patients discharged on DOACs were older, mostly male, and had lower rates of rheumatic heart disease than those on VKAs. During follow-up, no significant differences were observed in thromboembolic (hazard ratio, 0.754; 95% confidence interval, 0.496-1.145; P = .185) or major bleeding events (hazard ratio, 0.760; 95% confidence interval, 0.601-1.153; P = .197) between groups. A nonsignificant trend toward worse outcomes was noted for patients who discontinued or switched anticoagulation. CONCLUSIONS: In this large cohort of patients after mitral and/or aortic bioprosthesis implantation or mitral valve repair within the LAAOS III, DOACs showed similar thromboembolic and bleeding risks as VKAs, suggesting they may be a safe alternative.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Paparella D, Belley-Cote EP, Di Mauro M, et al. Oral anticoagulation in patients with atrial fibrillation and heart valve prosthesis: A substudy from the Left Atrial Appendage Occlusion Study (LAAOS) III trial. J Thorac Cardiovasc Surg. 2025. PMID: 40930379. doi:10.1016/j.jtcvs.2025.08.046

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。